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ABSTRACT In circulation, plasma glycoprotein vonWillebrand Factor plays an important role in hemostasis and in pathological
thrombosis under hydrodynamic forces. Mutations in the A1 domain of von Willebrand factor cause the hereditary types 2B and
2M von Willebrand disease that either enhance (2B) or inhibit (2M) the interaction of von Willebrand factor with the platelet
receptor glycoprotein Iba. To understand how type 2B and 2M mutations cause clinically opposite phenotypes, we use a combi-
nation of protein unfolding thermodynamics and atomic force microscopy to assess the effects of two type 2Bmutations (R1306Q
and I1309V) and a type 2M mutation (G1324S) on the conformational stability of the A1 domain and the single bond dissociation
kinetics of the A1-GPIba interaction. At physiological temperature, the type 2B mutations destabilize the structure of the A1
domain and shift the A1-GPIba catch to slip bonding to lower forces. Conversely, the type 2M mutation stabilizes the structure
of the A1 domain and shifts the A1-GPIba catch to slip bonding to higher forces. As a function of increasing A1 domain stability,
the bond lifetime at low force decreases and the critical force required for maximal bond lifetime increases. Our results are able to
distinguish the clinical phenotypes of these naturally occurring mutations from a thermodynamic and biophysical perspective that
provides a quantitative description of the allosteric coupling of A1 conformational stability with the force dependent catch to slip
bonding between A1 and GPIba.INTRODUCTION
Originally described by Erik von Willebrand in 1926, von
Willebrand disease (VWD) is the most common hereditary
bleeding disorder in humans (1). The inheritance of VWD
is autosomal dominant, affecting both sexes, and results
from a quantitative deficiency (types 1 and 3) and/or a qual-
itative abnormality (type 2) of the von Willebrand factor
(VWF) protein, whose primary role in hemostasis is to
initiate the adherence of platelets to the subendothelium at
sites of vascular injury (2,3).
VWF is a multidomain glycoprotein that is secreted into
the blood as a large multimeric polymer from vascular endo-
thelial cells. Mature VWF consists of a 2050-residue subunit
that contains multiple copies of A, B, C, and D type domains
that are arranged in the order D-D3-A1-A2-A3-D4-B1-B2-
B3-C1-C2-CK (cystine knot) (4–6). Under the influences
of blood flow, the interaction between VWF and platelets
is mediated by the A1 domain which binds the platelet glyco-
protein Iba (GPIba), contributing to the arrest of bleeding as
well as to the pathologic occlusion of diseased vessels under
elevated shear stress (7–10).
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0006-3495/09/07/0618/10 $2.00Two subtypes of type 2 VWD are characterized by either
enhanced (type 2B) or deficient (type 2M) platelet-VWF
interactions due to point mutations located specifically in
the A1 domain of VWF (11,12). Clinically, type 2B patients
are hyperresponsive to ristocetin-induced platelet agglutina-
tion due to the abnormally high affinity of VWF for platelet
GPIba. In addition, higher molecular weight multimers of
VWF are absent, presumably because the enhanced VWF
interaction with platelets increases its susceptibility to prote-
olysis by the enzyme, ADAMTS13. Conversely, type 2M
patients are typically insensitive to ristocetin-induced
platelet agglutination due to a low VWF affinity for platelet
GPIba and the multimerization of VWF is normal (3). These
contrary effects of type 2B and type 2M mutations on VWF
function emphasize the critical role of the A1 domain inter-
action with GPIba in primary hemostasis. However, the
structural basis by which these mutations cause clinically
opposite phenotypes is not understood.
We have applied equilibrium thermodynamics of protein
unfolding and kinetics of single-bond dissociation to elucidate
how two common type 2B mutations (R1306Q and I1309V)
and a type 2M mutation (G1324S) affect the intrinsic confor-
mational stability of A1 and the bond stability of the GPIba
interaction with A1. Fig. 1 illustrates the structural locations
of these clinical mutations in the A1 domain. We have per-
formed urea denaturation of A1 as a function of temperature,
with thermal denaturation of A1 by differential scanning
calorimetry and atomic force microscopy to assess structural
stability and the bond strength of the A1-GPIba interaction.
doi: 10.1016/j.bpj.2009.05.009
VWF A1 Stability and Binding to GPIba 619Previously, we have shown that urea unfolds the native
conformation of the A1 domain to an intermediate that has
significant secondary structure (13). Here we show that the
native conformation of A1 is destabilized by the type 2B
mutations and is stabilized by the type 2M mutation at phys-
iological temperature. We have also demonstrated previously
that the A1 domain forms catch bonds with GPIba, a property
that regulates platelet-rolling velocities on VWF as flow
increases (14). Here we show that both of the type 2B
mutations enhance bond lifetimes at low force, resulting in
a left-shift of the catch bond toward low force for I1309V
and a loss of a catch bond for R1306Q. In contrast, the type
2MG1324Smutation decreases the bond lifetime at low force
and right-shifts the catch bond toward higher forces than
observed for wild-type (WT) A1. These correlative observa-
tions demonstrate themutual relationship between the confor-
mational stability of VWF and its capacity to bind platelets at
physiological tethering forces. These observations also unite
equilibrium thermodynamics of protein stability with force-
dependent catch to slip-bond transitions that occur in proteins
involved in cellular adhesion. Our results suggest a funda-
mental mechanism by which the intrinsic stability of the A1
domain regulates the binding to GPIba, and provide the first
experimental evidence for conformational allostery in the
interaction between the VWFA1 domain and platelet GPIba.
METHODS
Recombinant WT, R1306Q, I1309V, and G1324S VWF-A1 domain vari-
ants were produced as previously described (15,8). Glycocalicin (the extra-
cellular fragment of GPIba) was purified from outdated human platelet-rich
FIGURE 1 Structure of the A1 domain with the type 2B, R1306Q and
I1309V, mutations indicated in red and the type 2M mutation, G1324S, in
blue. The disulfide bond is yellow. The structure was drawn using Chimera
(http://www.cgl.ucsf.edu/chimera/).plasma obtained from the Saint Luke’s Hospital Transfusion Services as
previously described (16).
All isothermal denaturationsof theWTA1domain and type2VWDmutants
were performed in 10 mM NaAcetate, 10 mM Phosphate, 10 mM Glycine,
150 mMNaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), pH¼ 8 buffer
at a protein concentration of 10 mM. The solutions of protein at each concen-
tration of urea or guanidiniumhydrochloride (GdmHCl)were allowed to equil-
ibrate at 5C and 15C overnight and at 25C and 35C for 4–6 h. Circular
dichroism was used to monitor the unfolding as previously described (13).
Differential scanning calorimetry (DSC)measurementswere performed on
a VP-DSC instrument (MicroCal, GE Healthcare, Piscataway, NJ) at 2 atm
after general guidelines for calorimetry (17). In all cases, 0.5mg/ml of protein,
was solubilized in 10 mM NaAcetate, 10 mM Phosphate, 10 mM Glycine,
150mMNaCl, 2mMEDTAat pH¼ 8.0. Thermal transitionswere calorimet-
rically irreversible due to protein aggregation at high temperature. All DSC
traces were corrected for an irreversible scan that was used as the baseline.
A detailed description of the thermodynamic phase diagram analysis of
the isothermal urea denaturations and the differential scanning calorimetry
analysis is provided in the Supporting Material along with the corresponding
data tables.
The atomic-force microscopy (AFM) force-clamp single-bond lifetime
measurement method has been described (14) using our custom-made
AFM (design adapted from V. Moy, University of Miami). Commercial
cantilevers (TM Microscopes, Sunnyvale, CA) with spring constants from
4 to 13 pN nm1 were calibrated by the thermal fluctuation method (18).
Briefly, 15 mL of WT or mutant A1 (10 mg/mL) was incubated on each of
two spots on a petri dish overnight at 4C. To reduce nonspecific binding,
a polystyrene petri dish was prewashed with absolute ethanol and dried
with argon gas at 4C overnight. The petri dish was washed three times
with phosphate-buffered saline (PBS) and blocked with PBS containing
1% bovine serum albumin. AFM cantilevers were soaked in PBS containing
1% bovine serum albumin (for negative control) or 10 mg/mL glycocalicin at
4C overnight. Lifetimes of GPIba/A1 bonds were measured in repeated test
cycles consisting of the following steps:
Step 1. Move the AFM tip to touch the Petri dish for 0.02 s.
Step 2. Retract it ~4 nm above the surface.
Step 3. Hold it for 1 s to allow for bond formation.
Step 4. Further retract it a predetermined distance, to see whether binding
occurs.
Step 5. If binding occurs, ramp to the preset force to determine whether
the bond survives.
Step 6. If the bond survives, measure the length of time until the bond
breaks (i.e., lifetime of the bond) at that force.
Step 7. Retract the AFM tip to the starting position.
Adhesion frequencies were <20%. Approximately twenty-percent of
adhesions yielded measurable lifetimes. Lifetime histograms were represen-
tative of those published in the literature (19,20). Each lifetime-versus-force
curve includes several hundreds of measurements (several tens of lifetime
measurements per force bin).
RESULTS
In the following, we first describe the denaturant and temper-
ature-dependent conformational stability of the A1 domain
containing the type 2B (R1306Q and I1309V) and 2M
(G1324S) mutations using the linear extrapolation and phase
diagram methods for isothermal urea-induced unfolding and
simplified Lumry-Eyring methods for the thermal unfolding.
After that, we proceed to the effects of these mutations on
the force-dependent-catch-to-slip-bond transitions in the
A1-GPIba interaction and demonstrate the relationship
between these two intrinsic properties of the A1 domain.Biophysical Journal 97(2) 618–627
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reversible unfolding of the A1 domain
Previously, we reported that the A1 domain unfolds in
a three-state manner through a well-defined intermediate
structure that does not fully denature in urea (13). In
Fig. 2, circular dichroism is used to monitor the unfolding
as a function of denaturant molarity which shows that guani-
dine HCl (GndHCl), a much stronger denaturant, is able to
fully resolve the second transition. Comparison of the urea
and GndHCl isothermal denaturations at 25C of WT A1
shows that the first transition from N#I in urea is shifted
to lower concentrations of GndHCl. The second transition,
I#D, which is only partially attained in urea, is fully
resolved at higher concentrations of GndHCl. It should be
noted that the unfolding of A1 induced by both urea and
GndHCl is fully reversible. Because of the high salt effects
that accompany GndHCl-induced protein denaturation, we
used GndHCl only for illustrating the three-state unfolding
character of the A1 domain. Hereafter, we use urea and
temperature to distinguish the effects of clinical mutations
on the structural stability of A1.
The stability proﬁle of the A1 domain assessed
by the phase diagram method
In Fig. 3, we report the isothermal urea denaturation of WT
A1, the type 2B VWD mutants, R1306Q and I1309V, and
the type 2M VWD mutant, G1324S, at 5C, 15C, 25C,
and 35C. The results of Fig. 3 illustrate some important
features of the structural transitions.
FIGURE 2 Urea and Guanidine HCl (GndHCl) denaturation of wild-type
VWF A1 domain at 25C monitored by circular dichroism at 222 nm to
illustrate the three-state character of the unfolding. Open symbols represent
the urea data and solid symbols represent the GndHCl data.Biophysical Journal 97(2) 618–627First, the native state secondary structure content of the
type 2 VWD A1 mutants is greater than for WT, as indicated
by the increased mean residue molar ellipticity.
Second, the clinical mutations only affect the N#I transi-
tion and the I#D transition is not altered by the mutations.
To confirm this, we also denatured these A1 domain mutants
with GndHCl at 25C and found that the I#D transitions
were identical for all protein mutants (data not shown). At
any given temperature, the secondary structure content of
the intermediate state is identical for all of the proteinmutants.
However, the secondary structure content of the intermediate
has a strong dependence on urea concentration, and as the
temperature is increased, the secondary structure of the inter-
mediate also increases, as is evident from the continual
decrease of the intermediate state baseline as a function of
temperature. This indicates that the structure of the interme-
diate is highly variable, resulting in expansionwith increasing
urea and contraction with increasing temperature.
Third, the type 2M G1324S mutation stabilizes the A1
domain, as is evident by the higher urea concentration
(greater c1/2) required to unfold the native structure. The
type 2B mutants, however, unfold within the same urea
concentrations as the WT A1 domain.
Fourth, the cooperativity of the urea unfolding (m-value)
for all the disease mutants, indicated by the width of the
transition, has greater temperature dependence than for the
WT A1 domain. The m-value distinguishes the thermody-
namic stability of type 2B mutants from WT, rather than
the c1/2 of the unfolding transition.
The phase diagram method illustrates these observations
more clearly (21). In Fig. 4, we have plotted all of the ther-
modynamic parameters obtained from the fitting of the data
in Fig. 3 to Eq. S1 in the Supporting Material along with the
results of a two-dimensional global fit of the data for all
temperatures and urea concentrations, Eq. S2 (lines), as a
function of temperature. The thermodynamic parameters
resulting from the phase diagram analysis are given in Table
S1. Fig. 4 shows the intrinsic stability against unfolding in
the absence of urea, DG0, the urea-induced unfolding coop-
erativity, m-value, the midpoint of the urea unfolding transi-
tion, c1/2, and the populations of native (N), intermediate (I),
and denatured (D) states as a function of temperature.
We first describe the energetics associated with the first
unfolding transition, N#I. Fig. 4 A shows that the native-
state stability of A1 containing the type 2M mutation,
G1324S (blue), is at all temperatures greater than the WT
A1. The type 2B mutations (red) at low temperatures are
slightly more stable than WT A1, but at physiological
temperature, these mutations cause A1 to become less stable
than WT. This stability trend is also evident by the melting
temperature, Tm, at which DG
0 ¼ 0. The Tm for G1324S
increases and the Tm for both type 2B mutants decreases
relative to WT A1 (Fig. 4 A and Table S1). Another feature
of the stability curves for the N#I transition is the increased
apparent heat capacity of unfolding (DCp
0) for the type 2
VWF A1 Stability and Binding to GPIba 621FIGURE 3 Urea denaturation of wild-type VWF A1 domain (black
circles), the type 2B VWD gain-of-function mutations R1306Q (red
squares) and I1309V (red diamonds), and the type 2M VWD loss-of-func-mutants of A1 relative to WT (Table S1), which results in the
increased curvature of the DG0 as a function of temperature.
DCp
0 is highly proportional to changes in solvent-accessible
surface area upon unfolding and an increase inDCp
0 as a result
of the mutation indicates that these mutants result in more
extensive unfolding than WT A1 (22–24).
Fig. 4B shows that the temperature dependence of the urea-
induced unfolding cooperativity for the mutations is greater
than WT, as is evident from the increased slope (vTm) of the
linear dependence of the m-value on temperature. Since
the m-value is directly representative of the size of the coop-
erative unit, a greater magnitude of m indicates a greater
amount of the protein structure participates in the unfolding
(22,24,25). At low temperature, where stability is maximal,
the size of the unfolding cooperative unit is larger than WT
for all clinical mutants. At higher temperatures, the greater
temperature dependence of m causes the size of the coopera-
tive unit to be comparable to WT for G1324S and to decrease
relative to WT for both of the type 2B mutants.
The urea-temperature phase diagram in Fig. 4 C, gives the
50% phase separation lines between states. The shape of the
curves are essentially thermal stability curves (DG0) that are
modified by the temperature-dependent m-value and they
define the regions on the urea-temperature plane where
conformational states of the A1 domain are populated (21).
The linear extrapolation model (see the Supporting Material)
states that the stability of a protein depends on the c1/2 as well
as them-value. Although the increased c1/2 required to unfold
the type 2MG1324Smutant results in its enhanced thermody-
namic stability over WT A1, the urea c1/2 of the type 2B
mutants (R1306L and I1309V) are very similar to WT A1.
The decreased stability of the type 2B mutants relative to
WT A1 at physiological temperature is a direct consequence
of the strongly temperature dependent m-values resulting
from these VWD mutations.
Finally, Fig. 4 D shows the populations of native, interme-
diate, and denatured states as a function of temperature. At
37C, the lower stability of the type 2B mutations signifi-
cantly increases the population of the intermediate confor-
mation. The intermediate is 13% populated for R1306Q
and 10% populated for I1309V, whereas, for WT, it is
only 3% populated. For G1324S, the population of the inter-
mediate state is negligible at physiological temperature.
For all the A1 mutants studied, the unfolding of the inter-
mediate structure from I#D is independent of the mutation.
Fig. 2 shows that relative to fully denatured state, this
partially folded intermediate has significant secondary struc-
ture and the thermodynamic stability of the intermediate is
greater than the native state stability (see Fig. 4 A, solid
symbols). Thermodynamically, classical two-state unfolding
only occurs if the stability of higher order structures exceeds
the stability of lower order structures (23). The three-state
tion mutation G1324S (blue triangles) at 5C, 15C, 25C, and 35C. Lines
represent the results of the fit of the data to Eq. S1.Biophysical Journal 97(2) 618–627
622 Auton et al.FIGURE 4 Temperature dependence of the thermody-
namic parameters derived from the isothermal urea-
induced unfolding of the VWF A1 domain shown in
Fig. 3. Symbols are identical to Fig. 3. (A) Thermodynamic
stability (DG0) of the A1 domain in the absence of urea as
a function of temperature defines the stability curve. (B)
Temperature dependence of the urea-induced unfolding
cooperativity (m-value). (C) Urea-temperature phase dia-
gram. Urea c1/2 versus temperature represents the 50%
phase separation line between the native and intermediate
states of A1 and between the intermediate and denatured
states of A1. (D) Populations of the native, intermediate,
and denatured states as a function of temperature. At
37C, the population of the intermediate for R1306Q is
13%, I1309V is 10%, WT is 3%, and G1324S is <0.1%.
The N#I transition is represented by open symbols and
the I#D transition by shaded circles. Data points represent
parameters derived from independent fits of the data in
Fig. 3 to Eq. S1 and lines represent the results of a global
fit of the data in Fig. 2 to Eq. S2.unfolding character of A1 results from the high stability of
the lower order structures making up the intermediate state,
which exceeds the native state stability. The thermal stability
of the intermediate is also associated with a very low
apparent heat capacity (Table S1) and the m-value of the
intermediate is less than the native state. This indicates that
the intermediate state retains a sizeable hydrophobic core
that can be forced to unfold in a cooperative manner with
high concentrations of denaturants. The intermediate state
also has a very high melting temperature Tm ¼ 945 12C,
indicating that the fully denatured state is never populated
under physiological conditions (Fig. 4 D). All of the afore-
mentioned observations indicate that the intermediate state
consists of an ensemble of conformations with different
degrees of residual structure. This variable thermodynamic
character of the intermediate state, as observed by urea-
induced expansion and temperature-induced contraction, is
the likely cause of the highly temperature dependentm-values
that we observe for the N#I transition.
Differential scanning calorimetry: irreversible
thermal denaturation of the A1 domain
in the absence of denaturant
Although the urea denaturation of the A1 domain is revers-
ible, thermal denaturation of the A1 domain is calorimetri-Biophysical Journal 97(2) 618–627cally irreversible as no thermal effect is observed in a second
heating of the protein solution. A characteristic of thermal
irreversibility is the scan rate dependence of the apparent
Ttrs (temperature at the maximum of the heat capacity
profile), which decreases with slower scan rates. The effect
of the scan rate on the calorimetric profiles indicates that
they correspond to irreversible, kinetically controlled transi-
tions, in aqueous solution. Comparing the DSC transitions in
Fig. 5 shows a net decrease in the apparent Ttrs values at all
temperature scan rates relative to WT A1 for both type 2B
mutants of A1 (R1306Q and I1309V) and an increase in
the apparent Ttrs for the type 2M G1324S mutant of A1
(Table S2). When analyzed by the two-state irreversible
model given by Eq. S5 and Eq. S6, the half-life at 37C,
calculated from the temperature dependence of the irrevers-
ible rate constant, decreases relative to WT for the type 2B
mutants and is substantially increased for the type 2Mmutant
(Table S2). Both of these observations indicate that the type
2B mutations destabilize the A1 domain and the type 2M
mutation stabilizes the A1 domain.
The most general mechanism of irreversible protein un-
folding is the Lumry-Eyring model, in which the native
conformation reversibly unfolds to an intermediate that is
irreversibly converted to a final state, N#I/F (26). The
fitting of the calorimetric data to Eq. S5 indicates that the
thermal denaturation of A1 proceeds without significant
VWF A1 Stability and Binding to GPIba 623population of the intermediate conformation of the protein
(I), N/ F. This limiting model of the thermal denaturation
does not mean that the native conformation of A1 undergoes
an irreversible alteration. As pointed out by Plaza del Pino
et al., the irreversible step is still I/ F as in the Lumry-Eyr-
ing model, but the rate of this step is fast, resulting in a low
population of the intermediate in the temperature range of the
DSC transition (27). The thermal irreversibility in the
absence of urea also does not contradict the conclusions
obtained from the reversible isothermal urea denaturation.
Lumry and Eyring, in their classical article on protein confor-
mational changes, stated that ‘‘hydrogen bonds between urea
molecules and peptide linkages appear to isolate individual
unfolded polypeptides to prevent, at least under mild condi-
tions of time and temperature, the polymolecular aggregation
which frequently establishes irreversibility in thermal trans-
conformations of secondary structures’’ (26). Furthermore,
in a more recent article, Rodriguez-Larrea et al. showed
that low concentrations of denaturants can restore thermal
reversibility (28).
Despite the thermal irreversibility in the absence of urea,
both thermodynamic analyses for isothermal urea denatur-
ation and differential scanning calorimetry are in qualitative
agreement showing that the type 2B mutants of A1 are desta-
bilized and the type 2M mutant of A1 is stabilized relative
to the WT A1 domain. These changes in conformational
stability are strongly correlated with the GPIba binding
properties of the A1 domain, as described in the next section.
AFM force-clamp single-bond lifetime
measurements
The results obtained from AFM experiments are an exten-
sion of our previous work, where we analyzed WT A1 and
the R1306Q mutation (14). Fig. 6 shows the force-dependent
lifetimes of single bonds of the interaction between the A1
domain and glycocalicin, the extracellular fragment of the
platelet GPIba surface receptor. Here, the bond lifetime of
the A1-glycocalicin interaction was measured as a function
of the applied force. In the case of the WT A1 domain, the
lifetimes of the interaction with glycocalicin exhibited
a biphasic character representative of a transition from catch
bonds at low force to slip bonds at higher force (Fig. 6). At
low bond force, increasing the force enhanced the bond life-
time (catch bond) until an optimal force was attained where
the bond lifetime was maximal (~20 pN). Further increases
in bond force resulted in decreased bond lifetimes (slip
bonds). The type 2M G1324S mutation shifted the catch-
bond character of the A1 domain to a higher bond force
required for maximal bond lifetime (~40 pN). The type 2B
FIGURE 5 DSC scans of the VWF A1 domain type 2B VWD gain-of-
function mutations R1306Q and I1309V (A and B), wild-type A1 (C), and
the type 2M VWD loss-of-function mutation G1324S (D) at scan rates
0.5 K/min (circles), 1.0 K/min (squares), and 1.5 K/min (diamonds). Lines
represent the results of the fit of the data to Eq. S5.Biophysical Journal 97(2) 618–627
624 Auton et al.FIGURE 6 A1-GPIba bond lifetime versus bond force for the type 2B
VWD gain-of-function mutations R1306Q and I1309V (A and B), the WT
A1 domain (C), and the type 2M VWD loss-of-function mutation G1324SBiophysical Journal 97(2) 618–627mutation I1309V decreased the force required for the catch
bond (~11 pN) and R1306Q abolished the catch bonds,
forming only slip bonds with maximal bond lifetimes at
the lowest applied force (<5 pN). These shifts in catch to
slip bonding between A1 and GPIba also change the bond
lifetime at low force. The bond lifetime at low force for
the type 2B mutations is enhanced relative to WT A1 and
diminished for the type 2M mutation.
Rank orders and correlations between
the mutational effects on intrinsic stability
of A1 and its capacity to bind GPIba
We have determined the effects of VWD type 2B and type
2M mutations on two fundamental properties of the A1
domain: the intrinsic thermodynamic stability of A1; and
the kinetics of the bond dissociation between A1 and GPIba.
From a thermodynamic point of view, we find that both type
2B mutations destabilize the A1 domain and the type 2M
mutation stabilizes the A1 domain. The rank order of the
mutational effects on conformational stability as given by
DG037C;N#I and Tm;N#I (Table S1) determined from the
phase diagram method and Ttrs, T* and the half-life (t37C)
(Table S2) determined from DSC is
R1306Q < I1309V < WT < G1324S:
That is, R1306Q is the least stable; I1309V is slightly more
stable, but still less stable than WT; and G1324S has the
greatest stability. This rank order is reversed when com-
paring the bond lifetime at the lowest force measured:
G1324S < WT < I1309V < R1306Q:
At low force, the system is essentially under equilibrium (or
near equilibrium), and the bond lifetime at low force is repre-
sentative of the intrinsic stability of the A1-GPIba bond. This
inverse relationship between conformational stability and
bond stability is shown in Fig. 7 A, where the bond lifetime
at low force is plotted against the thermodynamic stability,
DG0, or 1/DG0 (inset of Fig. 7 A), at 37C. The data are
inversely correlated and are well described by the empirical
relationship in Eq. 1, where the Constant ¼ 0.34 5 0.04
(kcal s mol1) with a correlation coefficient R ¼ 0.983,
tðsÞ ¼ Constant
DG0ðkcal=molÞ: (1)
Therefore, a decrease in the native state stability of A1 rela-
tive to the intermediate resulting from the type 2B mutations
will necessarily prolong low-force bond lifetime with
GPIba, whereas an increase in the native state stability of
A1 will shorten low-force bond lifetime with GPIba.
Comparing the mutational effects on the force required for
maximal bond lifetime between A1 and GPIba gives the
(D). The data in panels A and C were obtained from Yago et al. (14). The
data are presented as the mean5 the standard error of the mean.
VWF A1 Stability and Binding to GPIba 625same rank order as observed with conformational stability.
That is, the force required for maximal bond lifetime,
Fmax, is lowest for R1306Q and greatest for G1324S.
Fig. 7 B shows that increasing the conformational stability
of A1 also increases the force at maximal bond lifetime.
This force represents the transition from the catch to slip
bonds shown in Fig. 6 and its dependence on conformational
stability suggests that the force regulation of the A1-GPIba
dissociation is affected by the stability of A1. The most
stable mutant, G1324S, requires the highest force to induce
the transition from catch to slip bonds, whereas the least
stable mutant, R1306Q, requires a force that is too low to
be measured in our experiments.
DISCUSSION
The naturally occurring mutations in A1 domain of VWF
examined in this study result in the phenotypes associated
FIGURE 7 (A) Bond lifetime determined at low force (near equilibrium)
for the interaction between A1 and GPIba is inversely proportional to the
thermodynamic stability of the A1 domain at 37C. Shaded ellipses repre-
sent the error arcs for the experimental error on both the bond lifetime
and DG0. The fit to Eq. 1 was weighted according to the error on the lifetime
measurements. (Inset) Linear plot of bond lifetime versus 1/DG0. (B) Depen-
dence of the force required for maximal bond lifetime on the thermodynamic
stability of A1. As A1 stability increases, the force for maximal bond
lifetime also increases.with types 2B (R1306Q, I1309V) and 2M (G1324S) VWD
(29–31). Although all three of the mutations result in a
hemorrhagic disorder, the type 2B is characterized by a
gain-of-function phenotype in which the affinity of VWF
for platelet GPIba is enhanced, and therefore, platelet agglu-
tination occurs at a lower concentration of the modulator
ristocetin than normal plasma. Patients with the type 2M
G1324S mutation, which results in a loss-of-function (defec-
tive binding to GPIba) requires higher concentrations of ris-
tocetin than normal to induce platelet agglutination (31).
With these clinical observations in mind and the biophysical
results described, there are several important points to be
made to understand how these mutations alter the interaction
between VWF and platelets.
Structural studies of the A1 domain with the type 2B
mutations, R1306Q and I1309V, and A1 in complex with
GPIba, do not show significant conformational differences
when compared to the WT structure (32–36). How then
can the effects of these mutations be reconciled on a struc-
tural and conformational basis? We have approached this
dilemma from a thermodynamic rationale and it is important
to recognize that the thermodynamic studies are experiments
conducted under equilibrium in solution. That is, the confor-
mational stability of A1 determined at equilibrium represents
an intrinsic property of the domain. We have found that the
type 2B and 2M mutations have a significant effect on the
intrinsic conformational stability of the A1 domain. At phys-
iological temperature, type 2B mutations lower the stability
and the type 2M mutation, G1324S, increases the stability
of the A1 domain. Given the clinical observations of relative
VWF-GPIba affinity obtained from assays employing risto-
cetin, it is reasonable to hypothesize that a decreased confor-
mational stability of A1 enhances its interaction with GPIba,
whereas an increase in A1 stability diminishes its interaction
with GPIba.
Because VWF functions under hydrodynamic forces that
influence the structural stability of VWF, we have also
studied the effect of the mutations on the dissociation
kinetics of single A1-GPIba bonds as a function of force
by AFM. In these experiments, we observe a biphasic
force-dependent pattern of bond lifetime in three of four
cases, in which the bond lifetime increases with force to
a maximum and then decreases with force. In fact, we previ-
ously related this catch-bond to slip-bond transition to the
biphasic platelet rolling velocity on immobilized VWF as a
function of shear stress (14). The effect of the mutations
studied here is to shift this biphasic pattern either toward
higher force (type 2M) or to lower force (type 2B).
The interpretation of these results is twofold.
First, the bond lifetime observed at low force is represen-
tative of the intrinsic propensity of A1 to bind GPIba at equi-
librium. In this regime, the bond lifetimes for the type 2B
mutations are longer than observed for WT A1 and the
type 2M mutation has a decreased bond lifetime relative to
WT A1. Furthermore, the lifetimes of the A1-GPIbaBiophysical Journal 97(2) 618–627
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stability of A1. This inverse correlation supports the hypoth-
esis that a lower A1 stability enhances the affinity of VWF
for platelets and a higher A1 stability decreases VWF-
platelet affinity.
Second, the biphasic force dependence of the bond life-
times is representative of the nonequilibrium effects of rheo-
logical shear. The peak of the force curves is the critical force
required for the maximal bond lifetime for the A1-GPIba
interaction, and is directly correlated to the minimum of
the biphasic platelet rolling-velocity curves as a function of
shear rate that we recently described (14). This critical force,
Fmax, also has a functional dependence on the intrinsic
conformational stability of A1. As the stability is increased,
Fmax also increases, and this implies that the greater the
stability of A1, the greater the shear required for an optimal
interaction between VWF and platelets. Therefore, the
effects of VWD mutations on the intrinsic stability of A1
determine not only its equilibrium-binding propensity, but
also the degree of rheological shear required for an optimal
interaction with platelet GPIba.
Since the binding propensity of A1 to GPIba at equilib-
rium and under shear appears to be dependent on the intrinsic
conformational stability of A1, the significance of the inter-
mediate state is worth considering. At equilibrium, the un-
folding of A1 proceeds through an intermediate state. The
gain of function type 2B mutations decrease the stability of
the native conformation of A1 and in doing so, shift the equi-
librium in favor of this intermediate. At physiological
temperature, the equilibrium population of the intermediate
induced by the type 2B mutations is 10% or greater, which
is significantly higher than WT A1 (~3%). Although it is
not known whether the native to intermediate conformational
transition of A1 occurs in full-length or multimeric VWF,
our results support the idea that a VWF molecule containing
a mutation that decreases the stability of the A1 structure
could preferentially populate a conformation that exposes
the GPIba-binding site faster than WT VWF under low
hydrodynamic forces. Therefore, it would spontaneously
interact with platelets as described elsewhere (37). Within
this context, it is possible that the intermediate state of A1
has a greater affinity for platelet GPIba than the native state.
In this case, the effect of shear forces on VWF may tran-
siently shift the equilibrium in favor of the higher affinity
intermediate conformation of A1 resulting in a decreased
rate of dissociation and therefore an increased bond lifetime.
The combined effect of shear and the destabilizing type 2B
mutations investigated here may exacerbate this transient
equilibrium resulting in a higher population of the interme-
diate in the presence of rheological stress. In contrast, we
and others have demonstrated that the type 2M G1324S
mutation in A1 impairs the conformational change required
for the binding of VWF to GPIba (15,37). This inhibitory
effect of the G1324S mutation is likely a result of the
increased structural stability of the A1 domain that inhibitsBiophysical Journal 97(2) 618–627the conformational transition from the native to intermediate
state and restricts A1 to the low affinity native conformation.
The R1306Q mutation completely eliminates the catch-
bond phase and has a structural stability lower than the
I1309V mutation, which does not abolish the catch-bond
phase but shifts the biphasic pattern to lower force. Interest-
ingly, type 2B patients harboring either the R1306Q or the
I1309V mutation or other mutations may present different
clinical manifestations (38). For example, mild bleeding,
normal platelet count, and lack of highmolecular weight mul-
timers of VWF have been described in patients containing the
R1306Qmutation (39). Conversely, prolonged bleeding time,
low platelet count (thrombocytopenia), spontaneous platelet
aggregation, and some preservation of the high molecular
weight multimers of VWF in plasma have been observed in
patients with the I1309V mutation (30). In vivo, at high shear
rates, it is possible that the VWF R1306Qmutant cannot bind
firmly to platelet GPIba, preventing platelet clearance from
circulation and maintaining normal-to-moderate platelet
counts. Previously, we described an interaction between the
A1 and A2 domains (40) and it is possible that the effect
of R1306Q on A1 stability may induce the neighboring
A2 domain to effectively expose the cleavage site for
ADAMTS-13, thereby reducing the larger multimers of
VWF (41). On the other hand, at high shear rates, the VWF
I1309V mutant may bind stably to platelets promoting spon-
taneous platelet agglutination, which depletes VWF from
plasma and may cause thrombocytopenia. For the type 2M
G1324S mutant, the VWF fails to interact with platelets
because the mutation prevents the A1 domain from adopting
a conformation that exposes the binding site for GPIba.
Therefore, bleeding results from depletion of larger VWF
multimers from plasma, decreasing the platelet count and a
defective VWF-GPIba binding.
In summary, we have found that the type 2B and 2M
mutations have a significant effect on the intrinsic conforma-
tional stability of the A1 domain. Changes in the conforma-
tional stability of A1 directly affect the force-dependent
dissociation kinetics of VWF-GPIba interactions. We have
also demonstrated that platelet GPIba can form catch bonds
with type 2B VWF at low forces, which explains why throm-
bocytopenia can occur in type 2B von Willebrand Disease.
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